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Abstract: Purpose
Somatic variants in tumor necrosis factor receptor-associated factor 7 (  TRAF7  )
cause meningioma and other cancers, while germline variants have recently been
identified in seven patients with a syndrome associating cardiac, facial and digital
anomalies with developmental delay. We aimed to define the clinical and mutational
spectrum associated with  TRAF7  germline variants through identification and
description of 45 new patients, and to determine the effects of the variants at a
molecular level through transcriptomic analysis of patient fibroblasts.Methods
We performed exome, targeted capture and Sanger sequencing in a series of patients
with undiagnosed developmental disorders. Phenotypic and mutational comparisons
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were facilitated through data exchange platforms. Whole transcriptome sequencing
(RNA-Seq) was performed on RNA from patient- and control-derived
fibroblasts.Results
We identified heterozygous missense variants in  TRAF7  as the cause of a
developmental delay-malformation syndrome in 45 patients. Major features include a
recognizable facial gestalt (characterized in particular by blepharophimosis), short
neck, pectus carinatum, digital deviations and patent ductus arteriosus. Almost all
variants occur in the WD40 repeats of TRAF7 and most are recurrent. Dysregulation of
several genes, differentially-expressed in patient fibroblasts, plausibly contributes to
the pathogenesis of the disorder.Conclusion
We provide the first large-scale analysis of the clinical and mutational spectrum
associated with the  TRAF7  developmental syndrome, and we shed light on the
molecular etiology of the disorder through transcriptome studies.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
09 November 2019, Paris. 
 
Dear Editor, 
We would like to submit our manuscript entitled: “Phenotypic spectrum and transcriptomic profile 
associated with germline variants in TRAF7” by Castilla-Vallmanya and co-workers for 
consideration as an Article to Genetics in Medicine. 
Somatic variants in TRAF7 are known to cause meningioma, while germline TRAF7 variants have 
recently been identified in seven patients with a syndrome associating cardiac, facial and digital 
malformations with developmental delay/intellectual disability. In the submitted manuscript, we 
provide the first large-scale analysis of the clinical and mutational spectrum associated with the 
TRAF7 developmental syndrome, through identification and description of 45 new patients. Major 
features include a recognizable facial gestalt (characterized in particular by blepharophimosis), short 
neck, pectus carinatum, digital deviations and patent ductus arteriosus. Almost all variants identified 
are de novo heterozygous missense, occurring in the WD40 repeats of TRAF7. Intriguingly, the 
somatic mutations previously reported in meningiomas also occur in the WD40 repeats, but are non-
overlapping with the syndromic variants, suggesting different mechanisms of pathogenicity. 
We also performed RNA-Seq of TRAF7 syndrome patient fibroblasts, which led to the identification 
of several differentially-expressed genes, whose dysregulation plausibly contributes to the 
pathogenesis of the disorder. 
Our findings will improve genetic counseling options and medical care strategies for patients with 
variants in TRAF7 and will stimulate further investigation into the role of TRAF7 in embryonic 
development. 
All authors have read and approved the final version of the manuscript. 
We have included a competing financial interests statement in the manuscript (two authors are 
employees of GeneDx, Inc.). 
We have received and archived written consent for participation/publication from every individual 
whose data is included, including written consent to publish photographs (where applicable). 
We hope you will consider our manuscript for publication in Genetics in Medicine and we look 
forward to hearing your response. 
 
On behalf of all authors, 
Yours sincerely,  
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Purpose: Somatic variants in tumor necrosis factor receptor-associated factor 7 (TRAF7) cause 
meningioma and other cancers, while germline variants have recently been identified in seven 
patients with a syndrome associating cardiac, facial and digital anomalies with developmental 
delay. We aimed to define the clinical and mutational spectrum associated with TRAF7 germline 
variants through identification and description of 45 new patients, and to determine the effects of 
the variants at a molecular level through transcriptomic analysis of patient fibroblasts.  
Methods: We performed exome, targeted capture and Sanger sequencing in a series of patients 
with undiagnosed developmental disorders. Phenotypic and mutational comparisons were 
facilitated through data exchange platforms. Whole transcriptome sequencing (RNA-Seq) was 
performed on RNA from patient- and control-derived fibroblasts. 
Results: We identified heterozygous missense variants in TRAF7 as the cause of a developmental 
delay-malformation syndrome in 45 patients. Major features include a recognizable facial gestalt 
(characterized in particular by blepharophimosis), short neck, pectus carinatum, digital deviations 
and patent ductus arteriosus. Almost all variants occur in the WD40 repeats of TRAF7 and most 
are recurrent. Dysregulation of several genes, differentially-expressed in patient fibroblasts, 
plausibly contributes to the pathogenesis of the disorder. 
Conclusion: We provide the first large-scale analysis of the clinical and mutational spectrum 
associated with the TRAF7 developmental syndrome, and we shed light on the molecular etiology 
of the disorder through transcriptome studies. 
 





The tumor necrosis factor receptor (TNF-R)-associated factor (TRAF) family contains seven 
members defined by shared protein domains and their involvement in mediating signal 
transduction from TNF-R superfamily members.1 TRAF7 contains an N-terminal RING finger 
domain, an adjacent TRAF-type zinc finger domain, a coiled-coil domain and seven C-terminal 
WD40 repeats (Figure 1). The WD40 repeats are unique to TRAF7 within the TRAF family, with 
all other members instead containing a C-terminal TRAF domain. In vitro studies have suggested 
that TRAF7 plays a role in the regulation of several transcription factors through various 
mechanisms. It participates in the signal transduction of cellular stress stimuli, such as TNF 
stimulation, by activating pathways leading to increased transcriptional activity of AP1 and 
CHOP/gadd153.2–4 These effects are thought to be mediated by synergy between TRAF7 and the 
MAP3 kinase MEKK3, leading to the phosphorylation of JNK and p38 (regulators of AP1 and 
CHOP), with interaction of TRAF7 and MEKK3 occurring via the TRAF7 WD40 repeats.2,3 
Depending on the context, TRAF7 can positively or negatively regulate the activity of NF-B, 
through ubiquitination of pathway components p65 and NEMO.2,5,6 It also ubiquitinates p53,7 and 
the activity of the proto-oncogene c-Myb is negatively regulated by TRAF7 through sumoylation 
and consequent sequestering in the cytosol.8 In endothelial cells, TRAF7 interacts with the C-
terminus of ROBO4 to suppress hyperpermeability during inflammation.9 
Somatic missense variants in TRAF7, concentrated within the WD40 domains and frequently 
recurrent, have been identified in meningiomas, mesotheliomas, intraneural perineuriomas and 
adenomatoid tumors of the genital tract.10–17 Heterozygous germline variants in TRAF7 have 
recently been reported in seven patients with a developmental disorder involving cardiac, facial, 
and digital anomalies and developmental delay (OMIM #618164).18 Here, we refine our 
understanding of the TRAF7 mutational and phenotypic spectrum through the identification of 45 
previously undescribed patients, and thereby define a syndrome with a recognizable facial gestalt, 
specific skeletal and cardiac defects, and developmental delay/intellectual disability, which we 
propose to name the TRAF7 syndrome. Almost all identified variants fall in the WD40 repeats, 
most are recurrent and all are missense, suggestive of a gain-of-function or dominant negative 
mechanism, rather than haploinsufficiency. Intriguingly, somatic and germline variants do not 
overlap. We also present a transcriptomic analysis of fibroblasts from several patients, thereby 
providing insights into the pathways perturbed by TRAF7 alteration. 
 
 
Materials and Methods 
Variant identification 
Genetic testing was performed according to approved institutional ethical guidelines and consent 
was obtained from all families. Exome sequencing was performed in various centers worldwide, 
using standard approaches (details available upon request). Targeted capture sequencing of 
TRAF7, in a panel of genes implicated in craniofacial malformations, was performed during 
clinical diagnostic screening at the Necker Hospital, using a SureSelect kit (Agilent) for capture 
followed by sequencing on a HiSeq machine (Illumina). Polyphen-219 was used for predicting the 
pathogenicity of missense variants. 
 
Cell culture 
Fibroblasts were obtained from skin biopsies of four patients (age at biopsy range: 8 to 19 years) 
and six controls (age at biopsy range: 17 years to adult). Corresponding informed consent and 
institutional ethics approval were obtained (Ethics Committee of the Universitat de Barcelona, 
IRB00003099), and all methods were performed in accordance with the relevant guidelines and 
regulations. Fibroblasts were cultured in DMEM supplemented with 10% FBS (Gibco, 
LifeTechnologies) and 1% penicillin-streptomycin (Gibco, LifeTechnologies) and were 
maintained at 37ºC and 5% CO2. When appropriate, cells were treated with 10 ng/µl recombinant 
human TNFα protein (R&D systems) for 6, 24 or 48 hours.  
 
Cell viability assay 
Fibroblasts were plated in 96-well plates and synchronized through serum deprivation for 24 
hours. Cell viability was tested using an MTT assay, with a solution of 0.5 mg/ml Thiazolyl Blue 
Tetrazolium Bromide (Sigma-Aldrich) in DMEM (Gibco, LifeTechnologies). After 4 hours, 
formazan crystals were dissolved using DMSO (Merck Millipore) and absorbance was read at 
560 nm. 
 
Total RNA isolation and cDNA retrotranscription 
RNA was extracted from fibroblasts using the High Pure RNA Isolation Kit (Roche), following 
the manufacturer’s instructions. Integrity and purity of the RNA was tested by agarose gel 
electrophoresis and 260/230 and 260/280 absorbance ratios using an ND-1000 
Spectrophotometer (Nanodrop Technologies). All samples reached the quality and integrity 
standards for qRT-PCR. For RNA-Sequencing (RNA-Seq) analysis, the quality standards of half 
of the samples were tested on an Agilent Bioanalyzer 2100 (Agilent Technologies). RNA was 
retrotranscribed using the High-capacity cDNA Reverse Transcription kit (Applied Biosystems). 
 
RNA-Sequencing and data analysis 
RNA-Seq was performed by LEXOGEN, Inc. using the QuantSeq 3’ mRNA-Seq FWD kit for 
library preparation. Single-end reads were aligned to the human reference genome 
(GRCh37/hg19) and transcriptome using the STAR aligner. Quality metrics were obtained with 
tools of the RSEQC Quality control package. Differential expression analysis was performed 
using the R package DESeq2. The threshold to be considered as a differentially expressed gene 
(DEG) was set at a false discovery rate (FDR) ≤0.05 and a |log2 fold change| ≥1. 
 
Real-time PCR 
qPCR was performed using UPL probes (Roche), according to the manufacturer’s instructions. 
For every assay, the efficiency (E) of the reaction was calculated from a 7 point standard curve. 
Genomic DNA contamination was assessed and not detected in the samples. Amplification was 
done using the thermocycler Light Cycler 480 (Roche). Each sample was run in triplicate and the 
relative transcription level was quantified with the Crossing Point cycle calculation using the 
Light Cycler® 480 Software (release 1.5.0) (Roche). The GAPDH and PPIA genes were used as 
reference genes as they displayed the minimum coefficient of variation. The primer sequences 
and UPL probes used are available on request. 
 
Ingenuity pathway analysis 
Ingenuity Pathway Analysis (IPA, Qiagen) was performed on genes that showed an FDR ≤0.1 
and |log2 fold change| ≥0.38. Separate runs were performed for each treatment condition. IPA 
uses the Fisher’s Exact Test to calculate statistical significance, considering associations between 





Identification of pathogenic variants in TRAF7 
We performed exome sequencing, targeted capture sequencing and Sanger sequencing on 45 
individuals with undiagnosed, syndromic developmental delay/intellectual disability and 
dysmorphic facial features (Table S1). Comparison of phenotypes and variants was facilitated by 
the data exchange platforms GeneMatcher20 and DECIPHER.21 All 45 individuals harbored 
missense variants in TRAF7. The cohort includes 36 sporadic cases in which the TRAF7 variant 
was de novo, one patient with low level maternal mosaicism for the TRAF7 variant, five cases 
with unknown inheritance and one familial case (patients 24-26) in which affected dizygotic 
twins inherited a TRAF7 variant from their affected mother, in whom the variant arose de novo 
(Figure S1). Almost all variants occurred in the WD40 repeats (Figure 1). Patients 1, 2 and 4 are 
sporadic cases carrying TRAF7 variants of unknown inheritance in the coiled-coil domain, and 
display phenotypes only partly overlapping those frequently observed in the rest of the cohort 
(further details below). We therefore consider these three individuals as having TRAF7 variants 
of unknown significance. None of the variants present in patients 1-45 have been reported in the 
Genome Aggregation Database (gnomAD, dataset v2.1). All affect highly conserved amino acids 
(based on Multiz alignments of 100 vertebrates at the UCSC Genome Browser) and all (except 
one coiled-coil variant) are predicted possibly or probably damaging by Polyphen-2 (Table S2). 
The variants in the 45 patients occur at 20 amino acid positions (Figure 1); recurrent variants 
occur on eight of these, with the most recurrent by far being p.(Arg655Gln) (13 index cases). The 
remaining recurrent variants each occur in two to four index cases, and different variants of the 
same residue are observed at two positions (p.(Ser558Phe) or p.(Ser558Tyr); p.(Phe617Leu) or 
p.(Phe617Ser)). The finding of recurrent missense variants largely restricted to the WD40 repeats 
suggests a disease mechanism involving specific functional changes to the mutant TRAF7 
protein, rather than haploinsufficiency. In gnomAD, TRAF7 has a low probability of being loss-
of-function intolerant (pLI = 0.02), further suggesting haploinsufficiency of TRAF7 does not 
cause severe pediatric disease.  
 
Phenotype associated with TRAF7 variants 
Clinical details of all patients are provided in Table S1, and a summary of the phenotypes in the 
core cohort of 42 patients (i.e., excluding the three patients with coiled-coil variants of unknown 
significance) is provided in Table S3. Many patients presented with feeding difficulties (n=24), 
often requiring tube feeding in infancy. Short stature was noted in 12 cases, low weight in five 
and microcephaly or macrocephaly in a total of 10. All patients had some form of developmental 
delay; intellectual disability (n=23) and/or speech delay (n=29) occurred in all but a small 
minority, while motor delay occurred in the majority (n=30). Hypotonia was noted in 17 patients. 
Autism spectrum disorder was observed in six cases and epilepsy in seven. There was a range of 
nonspecific anomalies on brain MRI (most frequently, enlarged ventricles). Almost all patients 
presented with anomalies of the palpebral fissures; most frequently blepharophimosis (n=33), 
along with epicanthus (n=20), telecanthus (n=14), ptosis (n=19) and up- or downslanting 
palpebral fissures (n=11) (Figure 2). Hypertelorism was reported in 17 cases. Ear anomalies 
(n=27) most frequently consisted of low-set, posteriorly rotated and/or protruding ears. Other 
frequent facial features include a bulbous nasal tip (n=17), wide or flat nasal bridge (n=11), 
micro- or retrognathia, albeit typically mild (n=13) and a high or prominent forehead (n=11). A 
computational composite from multiple patient photos further highlights the facial gestalt of the 
syndrome (Figure S2). Other skull shape anomalies, such as trigonocephaly, dolicocephaly, 
plagiocephaly, brachycephaly or bitemporal narrowing, occurred in 18 cases, and 
craniosynostosis in three. Palatal anomalies (n=15) included submucous cleft and velopharyngeal 
insufficiency. Most patients presented with abnormalities of the extremities (Figure 3A). 
Although highly variable in nature, major anomalies of the hands were finger deviations (n=10), 
camptodactyly (n=10), brachydactyly (n=6) and syndactyly (n=5), and of the feet, overlapping 
toes (n=10), pes planus (n=10), varus or valgus abnormalities (n=10) and sandal gap (n=5). Joint 
limitation in the limbs, hypermobility and dislocations were occasionally present. Anomalies of 
the axial skeleton were frequent: short neck (n=24), pectus carinatum (n=17) and other chest 
shape anomalies (n=10, including barrel-shaped or narrow chest), rib anomalies (n=5), deviations 
of the vertebral column (n=7) and vertebral anomalies (n=14). Regarding the latter, cervical 
stenosis or spinal cord compression was of clinical concern in several cases. Congenital cardiac 
defects were also frequent: 24 patients had patent ductus arteriosus (many of which required 
surgical repair), nine had atrial and six had ventricular septal defects and 10 had anomalies of 
valves. Conductive and/or sensorineural hearing loss occurred in 21 cases. Anomalies of the eyes 
included refractive errors (n=10) and strabismus (n=10). Infrequent phenotypes included a range 
of kidney anomalies (n=10), cryptorchidism (n=7), hernias (n=11), inverted nipples (n=6) and 
lower limb edema (n=3). In addition to a similar facial appearance amongst many of the patients, 
other features contributed to an upper-body gestalt in several, i.e., short neck with sloping 
shoulders, pectus carinatum and relative macrocephaly (Figure 3B). Finally, amongst the few 
adult patients in our cohort (seven over 18 years), clinical signs of premature ageing22 were noted 
- two women (20 years and 44 years) had progressive hair loss, the latter also had premature 
atherosclerosis, and a 26 year old male had premature osteoporosis and hair loss.  
 
Amongst the differential diagnoses in our cohort, an Ohdo-related syndrome (OMIM 249620) 
was suspected in several patients, with KAT6B sequencing performed for five individuals prior to 
exome, highlighting that the TRAF7 syndrome overlaps with the group of blepharophimosis-
mental retardation syndromes23. Also, Noonan/RAS-MAPK pathway gene panels were tested in 
eight patients, suggesting similarities to rasopathies. Although almost all TRAF7 variants were 
identified through trio exome sequencing, inclusion of TRAF7 on an NGS panel of genes mutated 
in neurocristopathy and craniofacial malformation syndromes led to the identification of two 
further individuals through diagnostic screening (patients 5 and 29). In patients 38 and 42, a 
strong clinical suspicion of TRAF7 syndrome, based on comparison with our cohort at the time, 
led to identification of a TRAF7 variant through Sanger sequencing or reanalysis of a previously 
unresolved singleton exome, respectively, highlighting the recognizability of this syndrome. 
 
As noted above, three individuals (1, 2 and 4) harbored variants of unknown inheritance in the 
coiled-coil domain of TRAF7 (pink variants in Figure 1). These patients presented with 
neurodevelopmental defects, with seizures in two. Their facial features were not reminiscent of 
those of patients with variants in the WD40 repeats. Interestingly, patient 3, the only case with a 
de novo coiled-coil variant, had typical TRAF7 syndrome facial features (photographs were 
reviewed but permission to publish was denied). Of note, patient 4 had an endometrioid 
adenocarcinoma, diagnosed at 36 years. 
 
Syndromic TRAF7 missense variants affect gene expression 
As a first approach to understand the effects of syndromic TRAF7 missense variants, the 
expression of 17 genes was assessed by qRT-PCR using skin fibroblast RNA from three patients 
bearing different variants in the WD40 repeats [p.(Leu402Val), p.(Leu519Phe), p.(Arg655Gln); 
patient numbers 6, 13, 33, respectively] versus fibroblast RNA from six control individuals. Of 
these, 9 genes (EEF1A2, FLNB, IGFBP4, IGFBP7, LASS2, MMP2, NFKBIA, NOTCH3, 
SQSTM1) were selected because their expression appeared to be altered in a previous global 
transcriptome analysis performed in TRAF7-silenced cells,6 and because of their known 
involvement in human developmental disorders or putative role in developmental events relevant 
to the TRAF7 syndrome. The expression of JUN (encoding a subunit of the AP1 transcription 
factor) was tested because although AP1 activity can be stimulated by TRAF7, the effect of 
TRAF7 on transcription of AP1 components is unknown. TRAF7 itself was tested for auto-
regulation. The rest are known NF-κB target genes (CFLAR (cFLIP), CCL2 (MCP1), VEGFA, 
MYC, BCL2, PTGS2 (COX2)).24 The above genes were also tested after TNFα stimulation.  
We found NOTCH3 (ENSG00000074181) expression decreased by half in untreated patient cells 
(Figure 4), matching the direction of differential expression reported in TRAF7-silenced cells. In 
contrast, two other genes displayed an expression profile in patients opposite to that observed in 
TRAF7-silenced cells: FLNB (ENSG00000136068) expression levels in patients were over 2-fold 
higher than in controls, whereas IGFBP7 (ENSG00000163453) RNA was 4-fold lower in 
patients. We also found differences in BCL2 (ENSG00000171791), with lower expression levels 
in untreated patient cells than in controls, and PTGS2 (ENSG00000073756), whose expression 
was reduced to one third in untreated patient cells. Regarding TRAF7 itself, none of the three 
heterozygous missense variants tested altered its expression levels. In the same way, JUN, 
EEF1A2, IGFBP4, NFKBIA, LASS2, MMP2, SQSTM1, CFLAR, CCL2, VEGFA and MYC did not 
show any variation in their expression levels between patients and controls (data not shown).  
 
To further characterize the effects that syndromic TRAF7 missense variants could have on gene 
expression levels, we performed an mRNA transcriptomic analysis of skin fibroblasts. We used 
samples from the three patients and the six controls, with and without TNFα treatment. We 
considered DEGs as presenting an adjusted p-value <0.05 and |log2 fold change| in expression ≥1 
(Table S4). We identified 76 DEGs in basal conditions (51.31% up-regulated and 48.68% down-
regulated) and 90 DEGs after TNFα treatment (40% up-regulated and 60% down-regulated) 
(Figure 5A-5B). A substantial overlap in several DEGs was detected between the untreated and 
treated conditions, as 16 DEGs were up-regulated and 19 down-regulated independently of 
treatment (Figure 5C). In addition, 55 DEGs were identified only in the treatment condition, 
suggesting that TRAF7 syndromic variants may cause an alteration of the signaling pathway that 
is activated as a response to TNFα ligand. Table 1 summarizes the top 10 up- and down-regulated 
genes. 
Twelve DEGs were selected for qRT-PCR validation based on their high log2 fold change and/or 
functional criteria (i.e., for most, involvement in a human developmental disorder or relevant 
phenotype in an animal model – see Discussion for details) (Table S5). For this step, an 
additional patient [number 36, bearing the variant p.(Arg655Gln)] was included. Results for 
seven out of the 12 were confirmatory (ANGPT1, CASK, KIF26B, WNT5A, CFD, GPC6, 
KAZALD1) (Figure 4B). KRAS, which was slightly upregulated in the RNA-Seq analysis, 
appeared downregulated in treated patient cells by qRT-PCR, while RIT1 was slightly 
downregulated only in untreated cells by RNA-Seq and only in treated cells by qRT-PCR. 
Finally, three genes (FOXP1, SPTAN1, MAPK11) whose log2 fold changes and significance 
values were below the general threshold to be considered as DEGs, but which had been selected 
based on functional criteria, were not validated.  
To explore the different pathways and biological functions that might be affected, we performed 
IPA on the 726 DEGs identified under basal conditions using less stringent criteria than the 
preceding analyses (Table S6). The “Axonal guidance signaling” canonical pathway was 
significantly enriched, as 26 genes within this pathway showed alterations in transcript levels 
between patients and controls. Other significantly enriched canonical pathways included 
“Wnt/Ca2+ pathway” and “Role of NFAT in Cardiac Hypertrophy” (Figure 5D). IPA results also 
showed significant enrichment amongst the DEGs for genes involved in the development and 
function of the cardiovascular and nervous systems (Figure 5E). Similar results were obtained 
under TNFα-treated conditions (data not shown). 
 
Syndromic TRAF7 missense variants have mild effects on cell viability 
Putative differences in cell viability between patient and control fibroblasts were assessed, both 
in untreated and TNFα-treated conditions, during 24 or 48 hours. Although a slight tendency for 
increased cell viability was observed in patient fibroblasts under all conditions, significant 




In the present study, we have characterized the clinical features associated with germline variants 
in TRAF7, through analysis of 45 patients. In a cohort of seven patients, Tokita et al reported 
speech and motor delay, a range of dysmorphic facial features (including epicanthal folds, ptosis 
and dysmorphic ears), variable cardiac defects and anomalies of the extremities (digit deviations 
and variant creases) as principal phenotypes associated with TRAF7 variants.18 The large size of 
the cohort described here allowed us to further refine the phenotypic spectrum and to highlight 
several major phenotypes which were not emphasized previously: blepharophimosis, short neck, 
pectus carinatum and other thoracic defects, vertebral anomalies, patent ductus arteriosus and 
hearing loss. All the TRAF7 variants in our cohort are missense and several are recurrent, with 
one major mutational hotspot; p.(Arg655Gln). Previously, Tokita et al reported TRAF7 variants 
at only four positions (also missense); two in the coiled-coil domain and two in the WD40 repeats 
(including p.(Arg655Gln)).18 Our results reveal a highly skewed variant distribution along the 
protein, that was not evident in the prior study (Figure 1), and strongly implicate alteration of the 
WD40 repeats as the central disease mechanism.  
 
The germline TRAF7 variants reported here are strikingly mutually exclusive to the somatic 
variants previously identified in tumors (lower part of Figure 1). This is underscored by the 
presence of recurrent variants restricted to each disease; p.(Arg655Gln) identified in 13 index 
cases here but never previously reported in a tumor, and variants at Asn520 reported 39 times in 
meningioma11,12 but not in syndromic patients. This suggests differences in activity of the mutant 
protein in each disease (for example, disruption of different protein-protein interactions or 
differences in degree of the same activity). Interestingly, even amongst somatic variants, there 
may also be a trend for certain variants to be more frequent in particular tumor types; 
p.(His521Arg) and p.(Ser561Arg) (in blue in Figure 1) are highly recurrent in adenomatoid 
tumors of the genital tract,16 but have not been reported in meningiomas.10–13 In a few cases, the 
same amino acid is mutated to a different residue in each disease; for example, the syndromic 
variant p.(Leu519Phe) and the meningioma variants p.(Leu519Pro) and p.(Leu519Arg) (the latter 
two are not included in Figure 1). To the best of our knowledge, there is only one syndromic 
variant, p.(Arg524Trp) (de novo or maternal mosaic in four unrelated cases here) that has also 
been reported in a tumor sample.11 However, this meningioma also harbored a SMO variant, 
p.(Ala459Val), known to cause increased activity of SMO;25 the oncogenicity of the TRAF7 
variant in this case is therefore unclear. One patient in our series with a variant of unknown 
significance in the coiled-coil domain had an endometrioid adenocarcinoma, while no tumors 
were reported in the patients with variants in the WD40 domain (although only a few are adults). 
One patient (43 years of age) in the cohort of Tokita et al18 had a meningioma. Meningiomas 
harboring a TRAF7 variant typically also contain a variant in KLF4, AKT1 or PIK3CA,10–13 
suggesting a second hit may be required for development of TRAF7-associated tumors. Careful 
monitoring of aging syndromic patients will be required in order to determine whether they have 
a greater risk of developing tumors. 
 
WD40 repeats are typically protein- or nucleic acid-interaction surfaces,26 and the WD40 domain 
of TRAF7 is known to interact with MEKK32,3 and with the DNA-binding domain of c-Myb.8 
Whether alteration of these or other interactions underlies TRAF7 syndrome is unknown. 
Interestingly, Mekk3 is required for early cardiovascular development in mice.27 Also, 
phosphorylation of ERK1/2, which are MAP kinases downstream of MEKK3, is reduced in cells 
overexpressing TRAF7 syndromic variants,18 and loss of Erk2 in mice causes craniofacial and 
cardiac malformations and neurogenesis defects.28,29 In vitro overexpression of TRAF7 harboring 
WD40 domain variants identified in adenomatoid tumors of the genital tract leads to activation of 
the NF-B pathway,16 and although dysregulation of this pathway has not typically been 
associated with congenital malformations in humans,30 knock-out of Ikka (a central component of 
the NF-B pathway) in mice results in craniofacial and skeletal defects.31 The TRAF7 mutation 
distribution identified here, with clustering of recurrent missense variants in the WD40 repeats, is 
more consistent with a gain-of-function or dominant negative effect rather than 
haploinsufficiency. Structural studies suggest TRAF proteins can form trimers via the coiled-coil 
domain,32 and co-immunoprecipitation experiments have shown that TRAF7 can interact with 
itself2 and with TRAF6.33 An interesting possibility is that TRAF7 harboring syndromic variants 
could dominantly interfere not only with wildtype TRAF7 molecules but also with other TRAF 
proteins during development. TRAF7 loss of function animal models have not been reported. 
Amongst TRAF family members, Traf4 knock-out mice have congenital malformation 
phenotypes, including tracheal ring disruption, spina bifida and axial skeletal defects;34,35 the 
latter is of particular interest given the high frequency of costo-sternal and vertebral anomalies in 
TRAF7 syndrome patients. 
 
Tokita et al reported two TRAF7 syndrome patients with variants in the coiled-coil domain 
(p.(Lys346Glu) and p.(Arg371Gly)), although these had no or less negative effect on ERK1/2 
phosphorylation compared to the two WD40 repeat variants they identified (p.(Thr601Ala) and 
p.(Arg655Gln)). We report four individuals with coiled-coil domain variants, of which only one 
was confirmed to have a facial gestalt similar to patients with WD40 repeat variants. This 
suggests that some coiled-coil domain variants can have a similar molecular effect as those that 
perturb the WD40 domain. On the other hand, it has been reported that the coiled-coil domain of 
TRAF7 is required for interaction with NEMO,6 and in combination with the zinc finger domain 
for homodimerization and subcellular localization,2 raising the possibility that the molecular 
consequences of some coiled-coil domain variants may be different from those in the WD40 
repeats. Confirmation of the causality of all TRAF7 coiled-coil domain variants, and the 
associated phenotypic spectrum, will require further functional studies and analysis of a larger 
number of individuals in this mutational subset.  
 
To gain a better understanding of the pathogenic role of syndromic TRAF7 variants, patient 
fibroblasts were compared with controls at a transcriptomic level. As a first approach, 17 genes 
were selected and analyzed by qPCR. Nine of these genes had been found to be altered in 
TRAF7-silenced cells in previous studies.6 From these nine, only three showed differential 
expression in fibroblasts bearing TRAF7 syndromic variants compared to controls. In particular, 
FLNB was significantly increased in patients compared to controls (over 2-fold) independently of 
the treatment, as opposed to TRAF7 knock-down, which has been shown to lead to a reduction of 
FLNB expression.6 FLNB is an actin-binding protein that regulates dynamic changes of the 
cytoskeleton and has essential scaffolding functions. Given the skeletal malformations present in 
patients with TRAF7 variants, it is interesting that alterations in FLNB cause several skeletal 
dysplasias, including spondylocarpotarsal synostosis syndrome (OMIM #272460), Larsen 
syndrome (OMIM #150250), atelosteogenesis types I (OMIM #108720) and III (OMIM 
#108721) and boomerang dysplasia (OMIM #112310).36 IGFBP7 (also known as angiomodulin) 
was, on the other hand, underexpressed in patient fibroblasts independently of the treatment, 
while it was found overexpressed in TRAF7-depleted cells.6 It is a matrix-bound factor, with 
knockdown causing vascular patterning defects in zebrafish37 or inhibition of cardiogenesis in 
embryonic stem cells.38 A homozygous variant in humans causes retinal arterial macroaneurysm 
with supravalvular pulmonic stenosis (OMIM #614224).39 Reduced expression of IGFBP7 may 
contribute to the cardiovascular defects in TRAF7 syndrome patients. TRAF7 syndrome patient 
fibroblasts also expressed lower levels of NOTCH3. Notch3 knockout mice have defects in 
arterial differentiation and vascular smooth muscle cell maturation.40 Toxic neomorphic variants 
in NOTCH3 cause the cerebral arteriopathy CADASIL (OMIM #125310),41 while C-terminal 
truncating variants cause lateral meningocele syndrome (OMIM #130720), which includes 
craniofacial, skeletal and cardiac defects that partly overlap with those of the TRAF7 syndrome.42 
Given that the direction of gene expression changes in patient cells versus TRAF7-silenced cells 
can be divergent (FLNB, IGFBP7), the same (NOTCH3) or unchanged in patients, it is difficult to 
conclude on the basis of these experiments whether the TRAF7 variants are more likely gain or 
loss of function. The differences could stem from the cell types studied; previous studies on 
TRAF7-silencing were performed in an immortalized cell line6 while we have analyzed primary 
fibroblasts.  
 
Six other genes tested are downstream targets of NF-B and are involved in processes such as 
inflammation, tumorigenesis and negative regulation of apoptosis.24 From these, two genes 
showed significantly reduced expression in patient fibroblasts, namely BCL2 and PTGS2. BCL2 
is an anti-apoptotic factor that is deregulated in several human cancers.43 PTGS2 encodes COX2, 
which catalyzes the formation of the prostaglandin precursor PGH2 and is generally considered 
as an inflammation mediator.44 The expression of PTGS2 was reduced to one third in the patient 
fibroblasts without TNF treatment. Interestingly, COX2 deficiency has been associated with 
inefficient closure of the ductus arteriosus in mice45 and we observed patent ductus arteriosus in 
the majority of TRAF7 syndrome patients, suggesting a pathogenic effect of COX2 deficiency in 
this context.  
 
To further characterize the gene expression landscape in patients bearing syndromic TRAF7 
variants, we performed RNA-Seq of skin fibroblasts. Consistent with previous data suggesting 
that TRAF7 modulates the activity of several transcription factors, the expression of many genes 
was affected in patient cells. Pathway enrichment analysis of the identified DEGs highlighted 
pathways involved in the development and function of the nervous system, which could partly 
explain the intellectual disability present in patients harboring TRAF7 variants. Interestingly, the 
cardiovascular system category was also enriched for DEGs; congenital heart defects are frequent 
in TRAF7 syndrome patients. Several DEGs are especially interesting due to the role they play in 
specific cellular processes and the effects that their alteration can produce. ANGPT1, WNT5A and 
KIF26B were the most downregulated genes in patient fibroblasts under basal conditions. 
ANGPT1 encodes angiopoeitin 1 and homozygous knock-out in mice leads to severe vascular 
malformations and embryonic lethality.46 Conditional knock-outs in mice have shown roles for 
Angpt1 in cardiac morphogenesis47,48 and its deregulation may contribute to the cardiovascular 
anomalies observed in our cohort. Wnt5a is required for the outgrowth of limbs and craniofacial 
and genital structures in mice,49 and variants in WNT5A cause autosomal dominant Robinow 
syndrome (OMIM #180700), a condition which shares some skeletal features with the patients 
we report here.50 KIF26B encodes a kinesin required for kidney development in mice,51 and 
interestingly, together with WNT5A and ROR, it shapes a crucial noncanonical WNT pathway, 
especially relevant in cell migration events during embryogenesis.52 CASK, mildly downregulated 
in the patients, encodes a synaptic scaffolding protein. Loss of function variants in this gene are 
responsible for an X-linked syndrome associating intellectual disability, microcephaly and 
pontine and cerebellar hypoplasia (OMIM #300749).53 GPC6, KAZALD1 and CFD were among 
the most upregulated genes in TRAF7 syndrome patient fibroblasts. GPC6 encodes a member of 
the glypican family of cell-surface heparan sulfate proteoglycans, and GPC6 variants are 
responsible for a rare autosomal recessive condition defined by proximally shortened limbs; 
omodysplasia (OMIM #258315).54 KAZALD1 (also known as IGFPB-rP10) is expressed 
specifically in ossification regions of the head in mice and can promote osteoblast 
proliferation;55,56 KAZALD1 overexpression could therefore play a role in the craniofacial shape 
anomalies observed in TRAF7 syndrome patients. CFD encodes the complement factor D, a 
serine protease that acts in the alternative complement pathway. In humans, factor D deficiency 
leads to an immunologic condition with susceptibility to bacterial infections.57 The significance 
of CFD upregulation in TRAF7 syndrome patient cells is unclear. 
 
In conclusion, through analysis of a large series of patients, we have defined the phenotypic 
spectrum associated with germline TRAF7 variants. The major features in our series are 
intellectual disability, motor delay, a recognizable facial gestalt including blepharophimosis, 
short neck, pectus carinatum, digital deviations, hearing loss and patent ductus arteriosus. TRAF7 
syndrome patients typically require assisted learning and may be at risk of cervical stenosis. 
Older patients may benefit from monitoring for development of premature ageing phenotypes and 
tumors, although at this stage we cannot conclude whether there is an increased risk of the latter. 
We have shown there is a strong bias for TRAF7 syndrome-associated variants to occur in the 
WD40 repeats, and a major avenue for future investigation will involve determining whether 
there are different consequences on direction or strength of downstream signaling between these 
germline variants versus those previously reported in various cancers. Our transcriptomic studies 
of TRAF7 syndrome patient fibroblasts revealed a large number of DEGs. The fact that the 
expression of some genes (but not all) is only affected after TNF treatment indicates that 
TRAF7 function in this pathway is disturbed, but that this is not the only pathway affected by the 
syndromic variants. Several identified DEGs are involved in cardiovascular, skeletal or nervous 
system development or function, and are therefore relevant to the phenotypes observed in the 
patients. Further exploration of the link between TRAF7 and these putative transcriptional targets 
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Figure 1. TRAF7 variants. Domain boundaries drawn approximately to scale, based on ref6. 
Variants causing the TRAF7 syndrome are indicated in red (reported here) or grey (previously 
reported18). In pink, variants of unknown significance reported here. Beneath the protein, the 
most recurrent somatic variants (ie, in greater than five samples) are indicated; in black, those 
reported in meningiomas11,12 and in blue, those in adenomatoid tumors of the genital tract16. CC; 
coiled-coil. 
  
Figure 2. Facial features of patients with variants in TRAF7. Patient numbers are indicated at the 
top of each panel. See text for description of the major features. 
 
Figure 3. Anomalies of the extremities (A) and upper body appearance (B) of patients with 
variants in TRAF7. Patient numbers are indicated at the top of each panel. See text for description 
of the major features. 
 
Figure 4. qRT-PCR quantification of mRNA levels in TRAF7 syndrome patient fibroblasts. (A) 
qRT-PCR of BCL2, PTGS2, IGFBP7, NOTCH3, TRAF7 and FLNB in fibroblasts from three 
patients, with or without TNFα treatment. Relative mRNA level was normalized to the mean of 
six controls in each treatment condition (dotted line). GAPDH was used as a reference gene (the 
use of PPIA gave similar results). Data shown represents the mean ± SEM of the three patients, in 
six independent experiments. Asterisks indicate significant differences (p<0.05) between patients 
and controls in the corresponding condition (treated or untreated). (B) qRT-PCR validation of 
DEGs identified by RNA-Seq: ANGPT1, CASK, KIF26B, KRAS, RIT1, WNT5A, CFD, GPC6 and 
KAZALD1. Relative mRNA level was normalized to the mean of six controls in each treatment 
condition (dotted line). GAPDH was used as a reference gene (the use of PPIA gave similar 
results). Data shown represents the mean ± SEM of the four patients, in two independent 
experiments. Asterisks indicate significant differences (p<0.05) between patients and controls in 
the corresponding condition (treated or untreated). 
 
Figure 5. Transcriptome analysis of fibroblasts bearing missense TRAF7 variants. (A) Volcano 
plots representing differentially expressed genes (DEGs) in each condition (untreated or treated 
with TNFα (10 ng/ml) for 6 hours), measuring changes in expression (log2 fold change) and their 
significance (FDR; -log10 adjusted p-value). (B) Proportions of up- and down-regulated 
transcripts in untreated or treated patient fibroblasts. (C) Venn diagrams representing overlapping 
up- and down-regulated DEGs. (D and E) Ingenuity Pathway Analysis of DEGs in TRAF7 
syndrome patient fibroblasts. (D) Selected over-represented Canonical Pathways. The number of 
DEGs included in each pathway is specified and a -log10 p-value >1.3 was considered significant. 
(E) Selected over-represented categories of “Cellular Functions and Physiological System 
Development”. The number of DEGs associated with each category is specified and a -log10 p-




Table 1. Top 10 up- and down-regulated genes identified in TRAF7 syndrome patient fibroblasts 
by RNA-Seq. 
 
Supplementary Figure legends 
Supplementary Figure S1. Pedigree of the familial case (patients 24-26). 
 
Supplementary Figure S2. TRAF7 syndrome facial composite. The image was generated at 
Face2gene (https://www.face2gene.com) using one photo from each of 19 children with TRAF7 
syndrome. 
 
Supplementary Figure S3. MTT viability assay. Fibroblasts from four patients and six controls 
were exposed to TNFα (10 ng/ml) for 24 hours or 48 hours. Data represent the relative cell 
viability (mean ± SD) of three independent experiments (in triplicate). Significant differences are 




Supplementary Table S1. Detailed clinical features of patients studied in this report. A 
phenotypic description of patient 33 has been previously published (patient P6 in ref60). The 
TRAF7 variants of patients 6 and 8 were listed in ref61, without phenotypic information. 
ABR=auditory brainstem response; CMA=chromosomal microarray analysis; 
EEG=electroencephalogram; GERD= gastroesophageal reflux disease; ID=intellectual disability; 
IPS=integrated prenatal screening; MEP=motor evoked potential; NA=not available; NAp=not 
applicable; ND=not done; PPV=positive pressure ventilation; SGA=small for gestational age; 
SSEP=somatosensory evoked potential; VEEG=video electroencephalogram; VER=visual 
evoked response; VUS=variant of unknown significance; ES=exome sequencing. 
 
Supplementary Table S2. Characteristics of the TRAF7 variants identified in the 43 index cases. 
1Parentheses around patients 1, 2 and 4 indicate that their variants should be considered of 
unknown significance. 2cDNA coordinates refer to NM_032271.2.  
 
Supplementary Table S3. Summary of phenotypes associated with TRAF7 variants in the core 
cohort of 42 cases (patients 3 and 5-45). *, three patients born significantly prematurely are 
included within the total number of cases with patent ductus arteriosus. 
 
Supplementary Table S4. Detailed list of DEGs identified in TRAF7 syndrome patient 
fibroblasts by RNA-Seq. Only those DEGs with an adjusted p-value <0.05 and |log2 fold change| 
in expression ≥1 are listed. 
 
Supplementary Table S5. Genes selected for qPCR validation. T = transcriptomic criteria, i.e., 
high differential expression in the RNA-Seq data; F = functional criteria, i.e., for most, alteration 
in a relevant human disease or animal model. Note that KRAS, SPTAN1, CASK, MAPK11 and 
RIT1 did not meet the log2 fold change threshold for inclusion in the detailed DEG list in 
Supplementary Table S4. 
 
Supplementary Table S6. Complete list of significant IPA pathways and functions. Categories 
are ordered according to their p-values. A cutoff of 0.05 was chosen.  
 
Supplementary Table S7. Undiagnosed Diseases Network members list. 
Disclosure 
M.T.C. and S.Y. are employees of GeneDx, Inc. 
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Table 1. Top 10 up- and down-regulated genes identified in TRAF7 syndrome patient 
fibroblasts by RNA-Seq 
 - TNFα  + TNFα 










PCOLCE2 2.20 4.60 9.76E-04  CFD 2.12 4.34 2.89E-03 
CFD 2.19 4.56 1.34E-03  CCDC69 1.96 3.89 1.00E-02 
ABI3BP 2.11 4.31 1.98E-05  PCOLCE2 1.96 3.88 5.86E-03 
KLF4 1.90 3.74 1.26E-03  EFEMP1 1.85 3.59 4.07E-02 
ACKR3 1.89 3.71 4.74E-03  DMKN 1.77 3.41 3.18E-02 
DMKN 1.89 3.71 1.40E-02  ABI3BP 1.74 3.33 1.21E-03 
GPC6 1.85 3.60 1.24E-02  GPC6 1.72 3.30 3.01E-02 
PIM1 1.77 3.41 2.00E-04  SYPL2 1.70 3.25 3.91E-02 
RARRES3 1.64 3.11 3.19E-02  MITF 1.68 3.21 3.10E-03 












KIF26B -2.20 0.22 4.32E-04  LTB -2.45 0.18 5.57E-07 
ANGPT1 -2.07 0.24 9.95E-08  WNT5A -2.32 0.20 6.98E-04 
WNT5A -2.04 0.24 3.42E-03  IL1A -2.28 0.21 6.99E-03 
P2RX6 -1.94 0.26 2.11E-12  NR4A2 -2.21 0.22 1.82E-02 
COL27A1 -1.85 0.28 1.35E-04  GNA14 -2.14 0.23 1.56E-02 
IFI6 -1.77 0.29 8.49E-03  IL6 -1.98 0.25 4.59E-02 
FIGN -1.75 0.30 5.31E-05  ANGPT1 -1.94 0.26 1.22E-06 
TRIM16L -1.64 0.32 1.07E-03  CPXM2 -1.93 0.26 1.28E-02 
PIK3CD -1.63 0.32 6.06E-03  LRRN3 -1.88 0.27 1.51E-02 
TLE4 -1.62 0.33 2.61E-03  CYR61 -1.82 0.28 1.78E-03 
 
Table1









* whole exome sequencing
(24)
(25) (26)
Affected individuals: 24, 25, 26
FigureS1
FigureS2 Click here to access/download;Supplementary  (Appendix, online only material,
etc.);Figure S2 - TRAF7 Face2Gene composite.png
FigureS3 Click here to access/download;Supplementary  (Appendix, online only material,
etc.);Figure S3 - MTT assay v2.tif
 Supplementary Table S5. Genes selected for qPCR validation. 
    - TNFα    + TNFα        
Gene Ensembl Gene ID Log2FC FC FDR   Log2FC FC FDR   Validated 
Selection 
Criteria 
CFD ENSG00000197766 2.19 4.56 1.34E-03  2.12 4.34 2.89E-03  Yes T 
GPC6 ENSG00000183098 1.85 3.6 1.24E-02  1.72 3.3 3.01E-02  Yes T/F 
KAZALD1 ENSG00000107821 1.24 2.36 1.50E-02  1.64 3.12 6.09E-04  Yes T 
FOXP1 ENSG00000114861 1.02 2.03 7.08E-03  - - -  No F 
KRAS ENSG00000133703 0.85 1.8 1.07E-12  0.64 1.56 7.22E-07  No F 
SPTAN1 ENSG00000197694 0.51 1.43 3.67E-02  - - -  No F 
KIF26B ENSG00000162849 -2.2 0.22 4.32E-04  - - -  Yes T 
ANGPT1 ENSG00000154188 -2.07 0.24 9.95E-08  -1.94 0.26 1.22E-06  Yes T 
WNT5A ENSG00000114251 -2.04 0.24 3.42E-03  -2.32 0.2 6.98E-04  Yes T 
CASK ENSG00000147044 - - -  -0.84 0.56 3.12E-02  Yes F 
MAPK11 ENSG00000185386 -0.68 0.62 1.02E-03  -0.69 0.62 1.21E-03  No F 
RIT1 ENSG00000143622 -0.49 0.71 4.41E-02   - - -   No F 
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